<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109140">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744964</url>
  </required_header>
  <id_info>
    <org_study_id>0078-09-RBM</org_study_id>
    <nct_id>NCT01744964</nct_id>
  </id_info>
  <brief_title>Apomorphine Effects on Experimental Pain</brief_title>
  <official_title>Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study were to assess the effects of the dopamine agonist apomorphine on
      experimental pain models in healthy subjects and to explore the possible association between
      these effects and a common polymorphism within the dopamine transporter gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers (n=105) participated in this randomized double-blind, placebo-controlled,
      cross-over trial. Heat pain threshold and intensity, cold pain threshold, and the response
      to tonic cold pain (latency, intensity, and tolerance) were evaluated before and for up to
      120 min after the administration of 1.5 mg apomorphine/placebo. A polymorphism (DAT-1)
      within the dopamine transporter gene (SLC6A3) was investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Cold pain tolerance</measure>
    <time_frame>120 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assessment   of experimental pain models before and after treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apomorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assessment   of experimental pain models before and after treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apomorphine</intervention_name>
    <description>1.5 mg apomorphine</description>
    <arm_group_label>Apomorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - healthy and free from chronic pain of any type did not use any medications other than
        oral contraceptives were able to understand the purpose and instructions of the study.

        Exclusion Criteria:

        - any type of medical or painful condition use of medications or recreational drugs
        pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elon Eisenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus, Haifa, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 6, 2012</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apomorphine</keyword>
  <keyword>dopamine transporter gene</keyword>
  <keyword>SLC6A3</keyword>
  <keyword>cold pressor test</keyword>
  <keyword>tolerance</keyword>
  <keyword>experimental pain</keyword>
  <keyword>dopamine agonist</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apomorphine</mesh_term>
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
